Literature DB >> 20634454

Assessing targeted screening and low rates of HIV testing.

Leigh A Kennedy1, Fred M Gordin, Virginia L Kan.   

Abstract

OBJECTIVES: We assessed rates of HIV testing based on targeting patients with identified risk factors at the Veterans Affairs Medical Center in Washington, DC (VAMC-DC), where written informed consent along with pretest and posttest counseling had, until recently, been required by federal law.
METHODS: A cumulative retrospective review of the period 2000 through 2007 was conducted to assess the number of patients who were provided medical care at VAMC-DC, tested for HIV, and underwent confirmatory testing. Data on demographic characteristics and risks for HIV acquisition were also collected.
RESULTS: At VAMC-DC, 3.8% to 4.9% (mean=4.25%) of patients in care without known HIV infection underwent HIV screening annually. On average, HIV was confirmed at a yearly rate of 3.4% among those tested. During the study period, HIV prevalence ranged from 2.1% to 2.5%. Among patients receiving HIV care, 41.5% disclosed no risk factors for HIV acquisition.
CONCLUSIONS: Given that the HIV prevalence observed in this study was above 2% and that 41.5% of patients in care did not disclose any acquisition risks, targeted HIV screening has not been sufficient. HIV testing must be broadened and offered as part of routine medical care.

Entities:  

Mesh:

Year:  2010        PMID: 20634454      PMCID: PMC2920953          DOI: 10.2105/AJPH.2009.182790

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  14 in total

1.  Four of 10 with HIV get late diagnosis.

Authors:  N E Heltzer
Journal:  AIDS Read       Date:  2001-09

Review 2.  Why don't physicians test for HIV? A review of the US literature.

Authors:  Ryan C Burke; Kent A Sepkowitz; Kyle T Bernstein; Adam M Karpati; Julie E Myers; Benjamin W Tsoi; Elizabeth M Begier
Journal:  AIDS       Date:  2007-07-31       Impact factor: 4.177

3.  Simplifying consent increases HIV testing and new case detection: the San Francisco experience.

Authors:  Nicola M Zetola; Jeffrey D Klausner; Mitchell H Katz
Journal:  Am J Public Health       Date:  2009-09-17       Impact factor: 9.308

4.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Authors:  T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

5.  Integrated hepatitis C virus treatment: addressing comorbid substance use disorders and HIV infection.

Authors:  Marilyn S Huckans; Aaron D Blackwell; Todd A Harms; David W Indest; Peter Hauser
Journal:  AIDS       Date:  2005-10       Impact factor: 4.177

6.  Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.

Authors:  A David Paltiel; Rochelle P Walensky; Bruce R Schackman; George R Seage; Lauren M Mercincavage; Milton C Weinstein; Kenneth A Freedberg
Journal:  Ann Intern Med       Date:  2006-12-05       Impact factor: 25.391

7.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

8.  Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.

Authors:  Gillian D Sanders; Ahmed M Bayoumi; Vandana Sundaram; S Pinar Bilir; Christopher P Neukermans; Chara E Rydzak; Lena R Douglass; Laura C Lazzeroni; Mark Holodniy; Douglas K Owens
Journal:  N Engl J Med       Date:  2005-02-10       Impact factor: 91.245

9.  Expanded screening for HIV in the United States--an analysis of cost-effectiveness.

Authors:  A David Paltiel; Milton C Weinstein; April D Kimmel; George R Seage; Elena Losina; Hong Zhang; Kenneth A Freedberg; Rochelle P Walensky
Journal:  N Engl J Med       Date:  2005-02-10       Impact factor: 91.245

10.  HIV testing of at risk patients in a large integrated health care system.

Authors:  Douglas K Owens; Vandana Sundaram; Laura C Lazzeroni; Lena R Douglass; Patricia Tempio; Mark Holodniy; Gillian D Sanders; Vera M Shadle; Valerie C McWhorter; Teodora Agoncillo; Noreen Haren; Darlene Chavis; Leila H Borowsky; Elizabeth M Yano; Peter Jensen; Michael S Simberkoff; Samuel A Bozzette
Journal:  J Gen Intern Med       Date:  2007-03       Impact factor: 5.128

View more
  5 in total

1.  Routine HIV Screening in an Urban Community Health Center: Results from a Geographically Focused Implementation Science Program.

Authors:  Amy Nunn; Caitlin Towey; Philip A Chan; Sharon Parker; Emily Nichols; Patrick Oleskey; Annajane Yolken; Julia Harvey; Geetanjoli Banerjee; Thomas Stopka; Stacey Trooskin
Journal:  Public Health Rep       Date:  2016 Jan-Feb       Impact factor: 2.792

2.  Randomized comparison of universal and targeted HIV screening in the emergency department.

Authors:  Michael S Lyons; Christopher J Lindsell; Andrew H Ruffner; D Beth Wayne; Kimberly W Hart; Matthew I Sperling; Alexander T Trott; Carl J Fichtenbaum
Journal:  J Acquir Immune Defic Syndr       Date:  2013-11-01       Impact factor: 3.731

3.  Expanded HIV testing in the US Department of Veterans Affairs, 2009-2011.

Authors:  Maggie Czarnogorski; James Halloran Cns; Caitlin Pedati; Erin K Dursa; Janet Durfee; Richard Martinello; Victoria Davey; David Ross
Journal:  Am J Public Health       Date:  2013-10-17       Impact factor: 9.308

4.  Point-of-Care HIV Testing and Linkage in an Urban Cohort in the Southern US.

Authors:  Anne Zinski; Sarah M Dougherty; Ashutosh Tamhane; Kelly L Ross-Davis; James L Raper
Journal:  AIDS Res Treat       Date:  2013-09-17

Review 5.  Risk-Based Screening Tools to Optimise HIV Testing Services: a Systematic Review.

Authors:  J J Ong; K Coulthard; C Quinn; M J Tang; T Huynh; M S Jamil; R Baggaley; C Johnson
Journal:  Curr HIV/AIDS Rep       Date:  2022-02-11       Impact factor: 5.071

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.